Levetiracetam Tablet, Film Coated
Product Images NDC 63629-4675

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 63629-4675). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 01

The given text provides a formula to calculate the total daily dose of a medication based on the patient's weight and the recommended dose in mg/kg/day. The medication concentration is given as 100 mg/mL.*

FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 02

This text describes a formula used to estimate the renal function of female patients. The formula uses the patient's age, weight, and serum creatinine levels to calculate CLer, which is then adjusted to account for the patient's body surface area.*

FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 03

FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 04

This appears to be a chart or graph showing percentages related to two groups of individuals taking different amounts of Levetiracetam medication. Without more context or information, it is difficult to provide a more specific description.*

FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 05

This appears to be a chart or table displaying the percentages of patients in a study who received a placebo or different doses of a medication called Levetiracetam. The percentages range from 0% to 35.2%. However, without additional information, it is unclear what the study was investigating and what the percentages represent.*

FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 06

FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 07

This table displays the percentages of patients in a study who were either in the Placebo group or the Levetiracetam group. The first column shows the percentage of patients in the Placebo group and the second column shows the percentage of patients in the Levetiracetam group. The output does not provide any further information to determine the specifics of the study.*

FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 08

FDA Label Image

E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 09

This is a chart showing the percentage of patients in a study who fall under certain categories. The categories are shown on the left-hand side, and the percentages are on the right. The study compares a placebo group (with 84 participants) to a levetiracetam group (with 79 participants). The chart appears to show that neither group had 100% success in the outcome being measured. It is not clear what the outcome being measured is from the given text.*

FDA Label Image

Lbl636294675

This appears to be a label from a package of tablets named "Keppra 250mg," which is manufactured by Lupin Limited. The package contains 60 tablets and the expiration date is unspecified aside from showing "EXP MM/YY." The package was prepackaged by someone named Bryant Ranck. The label also includes a phone number and address for Bunbank, CA, as well as instructions to keep the medication away from children and store at a temperature of 20-25°C (68-77°F). The last line seems to include a barcode number.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.